A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer

Богуш, Е. А.; Равчеева, А. Б.; Богуш, Т. А.; Заботина, Т. Н.; Кадагидзе, З. Г.; Давыдов, М. И.

doi:10.1134/s1607672907020123

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct experiments to investigate tamoxifen effects on monoclonal antibody-Pgp binding in human chronic myelogeneous leukemia cell line K562 discovered that the antiestrogen competed with the antibody for the binding. 68 A similar result was obtained in a study of the effect of tamoxifen on the monoclonal antibody binding with MRP1 in human cervical carcinoma cell line HeLa. 69 In our experiments (T Bogush, E Dudko, E Bogush, B Polotsky, S Tjulandin, M Davydov, unpublished data, 2012 year) tamoxifen competitive interaction with Pgp, MRP1 and LRP was visualized by fluorescent microscopy.…”

Section: Interaction With Multidrug Resistance Proteinssupporting

confidence: 74%

Tamoxifen non-estrogen receptor mediated molecular targets

Богуш¹,

Dudko²,

Богуш³

et al. 2012

Oncol Rev

View full text Add to dashboard Cite

Recent experimental studies revealing new biological effects of tamoxifen on tumor cells both expressing and not expressing different types of estrogen receptors (ERα and ERβ) show new aspects of a seemingly well known agent. This review describes tamoxifen targets, the blocking of which leads to inhibition of tumor cell growth and angiogenesis, stimulation of programmed cell death (apoptosis, autophagia and necrosis), inhibition of multidrug resistance, invasion and metastasis. Since outcomes of tamoxifen action on cells are prognostically good from the point of view of both tumor growth/metastasis inhibition and tumor response to drug therapy, the authors believe this is an extremely important addition to tamoxifen antiestrogenic effect. Arguments are provided to consider the strategy of long-term tamoxifen treatment proposed by Professor Craig V. Jordan in the 1970s that is also applicable to the treatment of other tumors. This is, first of all, the fact that expression of estrogen receptor-beta that can also be targeted by tamoxifen therapy in solid tumors of practically all known sites and histologies. The authors believe that molecular biological screening of patients with respect to expression of tamoxifen cellular targets other than ERα and ERβ is needed to use to the full all tamoxifen biological activities other than modulation of estrogen receptors during long-term adjuvant therapy for cancers of various sites.

show abstract

Section: Interaction With Multidrug Resistance Proteinssupporting

confidence: 74%

Tamoxifen non-estrogen receptor mediated molecular targets

Богуш¹,

Dudko²,

Богуш³

et al. 2012

Oncol Rev

View full text Add to dashboard Cite

show abstract

“…To further validate Pgp as the potential target, tamoxifen was used to treat monoclonal antibody-Pgp in leukemia cell line K562, it was confirmed that tamoxifen competed with the antibody for the binding [ 37 ]. Another target confirmed using the same technique was MRP1 in human cervical carcinoma cell line HeLa [ 38 ].…”

Section: Tamoxifen Non- Er Targetsmentioning

confidence: 99%

“…Another target confirmed using the same technique was MRP1 in human cervical carcinoma cell line HeLa [ 38 ]. Results ascertain that tamoxifen interacts with major MDR markers Pgp, MRP1 and LRP, and this in turn affects how antitumor drugs bind to transporter proteins, consequently inhibits MDR mechanism [ 37 ]. It is worth mentioning that this kind of interaction might lead to a decrease in intracellular concentration of tamoxifen and thereof lower its ER mediated activities.…”

Section: Tamoxifen Non- Er Targetsmentioning

confidence: 99%

Tamoxifen and oxidative stress: an overlooked connection

et al. 2021

View full text Add to dashboard Cite

Tamoxifen is the gold standard drug for the treatment of breast cancer in pre and post-menopausal women. Its journey from a failing contraceptive to a blockbuster is an example of pharmaceutical innovation challenges. Tamoxifen has a wide range of pharmacological activities; a drug that was initially thought to work via a simple Estrogen receptor (ER) mechanism was proven to mediate its activity through several non-ER mechanisms. Here in we review the previous literature describing ER and non-ER targets of tamoxifen, we highlighted the overlooked connection between tamoxifen, tamoxifen apoptotic effects and oxidative stress.

show abstract